The Future of Feline Diabetes Mellitus – SGLT2 Inhibitors
In this podcast, Dr. Cassi is joined by Dr. Jocelyn Mott to discuss the use of SGLT2 inhibitors, an exciting new option in the world of feline diabetes mellitus. Their discussion includes mechanism of action of these drugs, practical applications and potential complications, and appropriate monitoring for patients managed with SGLT2 inhibitors. Elanco’s new SGLT2 inhibitor for the management of feline diabetes mellitus, Bexacat™ (bexagliflozin tablets), will also be discussed.